炎性蛋白复合指标在肺癌预后中的研究进展  

Research Progress of Inflammatory Protein Composite Index in the Prognosis of Lung Cancer

作　　者：轩晓倩 赵君慧[1] 

机构地区：[1]青海大学附属医院,青海 西宁

出　　处：《临床医学进展》2022年第6期5727-5731,共5页Advances in Clinical Medicine

摘　　要：肺癌是全球发病率第二、死亡率第一的恶性肿瘤,近年来随着基因检测技术及新药的广泛应用,肺癌的死亡率虽有所下降,但其预后仍较差。研究表明,肺癌是一种典型的炎症及代谢相关性疾病,本文就近年来肺癌中常见的炎性蛋白复合指标的研究进展作一系统综述。Lung cancer is the malignant tumor with the second morbidity and the first mortality rate in the world. In recent years, with the wide application of genetic testing technology and new drugs, the mortality rate of lung cancer has decreased, but its prognosis is still poor. The study shows that lung cancer is a typical inflammatory and metabolic related disease. This paper systematically summa-rizes the research progress of the common inflammatory protein composite index in lung cancer.

关 键 词：炎性指标 炎性相关蛋白 肺癌 预后 

分 类 号：R734.2[医药卫生—肿瘤]